Looking to sell Accutar Biotech stock or options?Contact us
Accutar Biotech is a developer of bio-pharmaceutical technology, aimed at hastening the process of drug discovery. The company employs computational drug design, supplemented by wet-lab validation. They offer services like ligand docking with side-chain flexibility, virtual screening, and prediction of a drug's ADME properties. This facilitates researchers in significantly reducing the time and expense typically involved in traditional drug discovery processes.
Hedosophia, CMS Ventures, Karista (Paris), YITU, Mirae Asset Capital, 5Y Capital, Yunfeng Capital, 3W Partners Capital, Newton BioCapital, Primavera Capital Group, CDH Investments, ZhenFund, IDG Capital.
We have an even better solution: The Collective Exchange Fund
Get in touch and see if we can help you